CD4 T-cell Immunotherapy for Chronic Viral Infections and Cancer

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2013 Sep 4

PMID 23998732

Citations 37

Authors

Alice O Kamphorst

Rafi Ahmed

Affiliations

Soon will be listed here.

Abstract

During chronic infections and cancer, T cells progressively lose function and become exhausted. However, effective T-cell responses are necessary to ultimately control viral infections and tumors. Hence, strategies that either restore endogenous immune responses or provide functional T cells by adoptive immunotherapy need to be explored. CD8 T cells play a prominent role in viral infections, as well as cancer, but CD4 T cells are necessary to support CD8 T-cell function. In addition, CD4 T cells exert direct effector functions, induce optimal B-cell responses and orchestrate innate immunity. Therefore, we propose that adoptive transfer strategies should exploit CD4 T cells alone or in combination with CD8 T cells, for the treatment of chronic infections and cancer. Furthermore, since adoptively transferred cells are subject to exhaustion, combining adoptive transfer therapy with immunotherapies that inhibit T-cell exhaustion should maximize the longevity and success rate of responses.

Citing Articles

Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.

Wittling M, Knochelmann H, Wyatt M, Rangel Rivera G, Cole A, Lesinski G J Immunother Cancer. 2024; 12(6).

PMID: 38945552 PMC: 11216073. DOI: 10.1136/jitc-2023-008715.

Identification and validation of molecular subtypes and prognostic signature for stage I and stage II gastric cancer based on neutrophil extracellular traps.

Mu L, Qiu G Open Med (Wars). 2024; 19(1):20230860.

PMID: 38221932 PMC: 10787308. DOI: 10.1515/med-2023-0860.

A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.

Meng W, Chen B, Jiang Z, Cai B, Ma L, Guan Y Transl Cancer Res. 2023; 12(8):2071-2098.

PMID: 37701098 PMC: 10493793. DOI: 10.21037/tcr-23-227.

Circulating Hsp70 Levels and the Immunophenotype of Peripheral Blood Lymphocytes as Potential Biomarkers for Advanced Lung Cancer and Therapy Failure after Surgery.

Safi S, Messner L, Kliebisch M, Eggert L, Ceylangil C, Lennartz P Biomolecules. 2023; 13(5).

PMID: 37238744 PMC: 10216400. DOI: 10.3390/biom13050874.

Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa.

Tartaglia G, Park P, Alexander M, Nystrom A, Rosenbloom J, South A Biomolecules. 2023; 13(5).

PMID: 37238610 PMC: 10216840. DOI: 10.3390/biom13050740.

References

Dudley M, Wunderlich J, Shelton T, Even J, Rosenberg S . Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26(4):332-42. PMC: 2305721. DOI: 10.1097/00002371-200307000-00005. View

Papadopoulos E, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi M . Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330(17):1185-91. DOI: 10.1056/NEJM199404283301703. View

Day C, Kaufmann D, Kiepiela P, Brown J, Moodley E, Reddy S . PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006; 443(7109):350-4. DOI: 10.1038/nature05115. View

Bachmann M, Hunziker L, Zinkernagel R, Storni T, Kopf M . Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur J Immunol. 2004; 34(2):317-26. DOI: 10.1002/eji.200324717. View

Marshall N, Swain S . Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol. 2011; 2011:954602. PMC: 3228492. DOI: 10.1155/2011/954602. View

Kochenderfer J, Rosenberg S . Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013; 10(5):267-76. PMC: 6322669. DOI: 10.1038/nrclinonc.2013.46. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

10.

Virgin H, Wherry E, Ahmed R . Redefining chronic viral infection. Cell. 2009; 138(1):30-50. DOI: 10.1016/j.cell.2009.06.036. View

11.

Blattman J, Grayson J, Wherry E, Kaech S, Smith K, Ahmed R . Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003; 9(5):540-7. DOI: 10.1038/nm866. View

12.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

13.

Gamadia L, Remmerswaal E, Weel J, Bemelman F, van Lier R, Ten Berge I . Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2002; 101(7):2686-92. DOI: 10.1182/blood-2002-08-2502. View

14.

Brown D, Lee S, Garcia-Hernandez M, Swain S . Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol. 2012; 86(12):6792-803. PMC: 3393557. DOI: 10.1128/JVI.07172-11. View

15.

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

16.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

17.

Bergthaler A, Flatz L, Verschoor A, Hegazy A, Holdener M, Fink K . Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol. 2009; 7(4):e1000080. PMC: 2672599. DOI: 10.1371/journal.pbio.1000080. View

18.

Topalian S, Rivoltini L, Mancini M, Markus N, Robbins P, Kawakami Y . Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A. 1994; 91(20):9461-5. PMC: 44832. DOI: 10.1073/pnas.91.20.9461. View

19.

Matloubian M, Concepcion R, Ahmed R . CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994; 68(12):8056-63. PMC: 237269. DOI: 10.1128/JVI.68.12.8056-8063.1994. View

20.

Hui C, Lie A, Au W, Leung Y, Ma S, Cheung W . A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood. 2005; 106(2):464-9. DOI: 10.1182/blood-2005-02-0698. View